Skip to main content

Advertisement

SpringerLink
Log in

Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Alteration and overexpression of HER2 proto-oncogene have been implicated in the carcinogenesis and prognosis of ovarian cancer. We evaluated this hypothesis among women with ovarian carcinoma patients from Tiruchirapalli, Tamil Nadu, India.

Methods

Genomic DNA was extracted from 72 case patients and 288 control subjects and was examined for I655V polymorphism by PCR–RFLP based assay. Immunohistochemistry analysis was carried out in order to study the overexpression of HER2 protein. The observed number of each genotype was compared with that expected for a population in the Hardy–Weinberg equilibrium. In analysing the relation between genotype and overexpression of HER2 protein, Cochran-Mantel–Haenszel statistics was used.

Results

We found that 20.8 % of the case patients and 16.3 % of the control subjects were heterozygous for the Val allele and 10 case patients (13.8 %) and 3 control subjects (1.1 %) were homozygous for this allele (P < 0.001). Compared with women with Ile/Ile genotype, women with Val/Val genotype had an elevated risk of ovarian cancer. The genotype distributions were consistent with the Hardy–Weinberg equilibrium. The risk increased with the number of Val allele and women homozygous for the Val allele had 15-fold (OR = 15.3; 95 %CI = 4.09–57.31) increased risk of cancer. The patients homozygous for the Valine allele showed strong HER2 protein expression.

Conclusion

The results showed that the valine allele may be an indicator of genetic susceptibility to ovarian carcinoma in the study population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gadducci A, Cosio S, Gargini A et al (2004) Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecol Endocrinol 19:216–228

    Article  PubMed  CAS  Google Scholar 

  2. Tingulstad S, Skjeldestad FE, Halvorsen TB et al (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885–891

    Article  PubMed  Google Scholar 

  3. Parazzini F, Franceschi S, La Vecchia C et al (1990) Review: the epidemiology of ovarian cancer. Gynecol Oncol 43:9–23

    Article  Google Scholar 

  4. National Cancer Registry Program (2010) Three year report of population based cancer registries (2006–2008), Bangalore, India

  5. Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645–656

    Article  PubMed  CAS  Google Scholar 

  6. Medeiros R, Pereira D, Afonso N et al (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156–161

    Article  PubMed  CAS  Google Scholar 

  7. Roskoski R (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319:1–11

    Article  PubMed  CAS  Google Scholar 

  8. Akiyama T, Sudo C, Ogawara H et al (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646

    Article  PubMed  CAS  Google Scholar 

  9. Graus-Porta D, Beerli RR, Daly JM et al (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. Eur Med Biol Org J 16:1647–1655

    CAS  Google Scholar 

  10. Sliwkowsk MX, Schaefer G, Akita RW et al (1994) Coexpression of erbB-2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:14661–14665

    Google Scholar 

  11. Di Fiore PP, Pierce JH, Kraus MH et al (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182

    Article  PubMed  Google Scholar 

  12. Stern DF, Kamps MP, Cao H (1988) Oncogene activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969–3973

    PubMed  CAS  Google Scholar 

  13. Papewalis J, Nikitin AY, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452

    Article  PubMed  CAS  Google Scholar 

  14. Hishida A, Hamajima N, Iwata H et al (2002) Re: population-based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807–1808

    Article  PubMed  CAS  Google Scholar 

  15. Xie D, Shu XO, Deng Z et al (2000) Population-based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417

    Article  PubMed  CAS  Google Scholar 

  16. Mullenbach R, Lagoda PJ, Welter C (1989) An efficient salt–chloroform extraction of DNA from blood and tissues. Trends Genet 5:391

    PubMed  CAS  Google Scholar 

  17. Pinto D, Pereira D, Portela C et al (2005) The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335:1173–1178

    Article  PubMed  CAS  Google Scholar 

  18. Spitz MR, Wu X, Mills G (2005) Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23:267–275

    Article  PubMed  Google Scholar 

  19. Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657

    Article  PubMed  CAS  Google Scholar 

  20. Guy CT, Webster MA, Schaller M et al (1992) Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. PNAS 89:10578–10582

    Article  PubMed  CAS  Google Scholar 

  21. Keshava C, McCanlies EC, Keshava N et al (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37–41

    Article  PubMed  CAS  Google Scholar 

  22. Millikan R, Eaton A, Worley K et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African American and whites. Breast Cancer Res Treat 79:355–364

    Article  PubMed  CAS  Google Scholar 

  23. Ameyaw MM, Thornton N, McLeod HL (2000) Re: population based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:1947

    Article  PubMed  CAS  Google Scholar 

  24. Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260–263

    Article  PubMed  CAS  Google Scholar 

  25. Fasching PA, Gayther S, Pearce L (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol oncol 3:171–181

    Article  PubMed  CAS  Google Scholar 

  26. Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular activation switch in the transmembrane domain of erbB2. PNAS 99:15937–15940

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors greatly acknowledge Indian Council of Medical Research, New Delhi for the financial support (3/2/2/63/2011/NCD-III; 5/13/88/06/NCD-III). The authors acknowledge the Vice Chancellor of Bharathidasan University for providing the infrastructure facility to carry out the research work. The authors thank Dr. V. J. Senthil, Director, GVN Institute of Cancer, India.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Microbiology, Medical Microbiology Laboratory, School of Life Sciences, Bharathidasan University, Tiruchirappalli, 620 024, Tamil Nadu, India

    Santhanam Shanmughapriya, Krishnakumar Vinodhini & Kalimuthusamy Natarajaseenivasan

  2. Department of Surgical Oncology, Dr. GVN Institute of Cancer, Tiruchirappalli, Tamil Nadu, India

    G. Senthilkumar

  3. Department of Medical Oncology, Dr. GVN Institute of Cancer, Tiruchirappalli, Tamil Nadu, India

    Seshachalam Arun

  4. Department of Biotechnology, Manonmaniam Sundaranar University, Alwarkurichi, Tamil Nadu, India

    Sivasubramanian Sudhakar

Authors
  1. Santhanam Shanmughapriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Senthilkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seshachalam Arun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Krishnakumar Vinodhini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sivasubramanian Sudhakar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kalimuthusamy Natarajaseenivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kalimuthusamy Natarajaseenivasan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shanmughapriya, S., Senthilkumar, G., Arun, S. et al. Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India. Arch Gynecol Obstet 288, 1385–1390 (2013). https://doi.org/10.1007/s00404-013-2892-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2892-y

Keywords

Search

Navigation